In This Article:
As global markets continue to react positively to the Trump administration's emerging policies, with U.S. stocks reaching record highs and growth stocks outperforming value shares, investors are increasingly focused on companies that demonstrate robust growth potential and strong insider ownership. In such a dynamic environment, firms where insiders hold significant stakes can signal confidence in the company's future prospects, making them attractive considerations for those seeking growth opportunities in an evolving market landscape.
Top 10 Growth Companies With High Insider Ownership
| Name | Insider Ownership | Earnings Growth |
| Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3) | 17.3% | 20.5% |
| Seojin SystemLtd (KOSDAQ:A178320) | 32.1% | 39.9% |
| SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
| Propel Holdings (TSX:PRL) | 36.5% | 38.9% |
| On Holding (NYSE:ONON) | 19.1% | 29.7% |
| Pharma Mar (BME:PHM) | 11.9% | 55.1% |
| Kingstone Companies (NasdaqCM:KINS) | 20.8% | 24.9% |
| Fine M-TecLTD (KOSDAQ:A441270) | 17.2% | 135% |
| Elliptic Laboratories (OB:ELABS) | 26.8% | 121.1% |
| Fulin Precision (SZSE:300432) | 13.6% | 71% |
Let's explore several standout options from the results in the screener.
Genomictree
Simply Wall St Growth Rating: ★★★★★☆
Overview: Genomictree Inc. is a biomarker-based molecular diagnostics company that develops and commercializes products for detecting cancer and infectious diseases, with a market cap of approximately ₩463.01 billion.
Operations: The company's revenue is primarily derived from its Cancer Molecular Diagnosis Business, which generated ₩2.06 billion, and its Genomic Analysis and Other Business, contributing ₩144 million.
Insider Ownership: 16.1%
Earnings Growth Forecast: 115.9% p.a.
Genomictree is trading at 68.5% below its estimated fair value, suggesting potential undervaluation. Despite having a highly volatile share price recently, the company is expected to become profitable in the next three years with earnings forecasted to grow significantly at 115.9% annually. However, it currently lacks meaningful revenue (₩2 billion) and its Return on Equity is projected to remain low at 5.7%. No substantial insider trading activity has been reported over the past three months.
-
Click to explore a detailed breakdown of our findings in Genomictree's earnings growth report.
-
Our valuation report unveils the possibility Genomictree's shares may be trading at a premium.
Akatsuki
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Akatsuki Inc. operates in the gaming, comic, and related industries primarily in Japan, with a market cap of ¥42.83 billion.